The dysregulation of phosphatidylinositol 3-kinase (PI3K)-dependent pathways is implicated in several human cancers making it an attractive target for small molecule PI3K inhibitors. A series of potent pyridyltriazine-containing inhibitors of class Ia PI3Ks were synthesized and a subset of compounds was evaluated in exploratory repeat-dose rat toxicology studies. Daily oral dosing of compound 1 in Sprague Dawley rats for four consecutive days was associated with hepatobiliary toxicity that included biliary epithelial hyperplasia and hypertrophy, periductular edema, biliary stasis, and acute peribiliary inflammatory infiltrates. These histological changes were associated with clinical pathology changes that included increased serum liver enzymes, total bile acids, and bilirubin. The predominant clearance pathway of 1 was shown in vitro and in a bile-duct cannulated rat 14 C-ADME study to be P450-mediated oxidative metabolism. An O-demethylated pyridine metabolite, M3, was identified as a candidate proximal metabolite that caused the hepatotoxicity. Co-administration of the pan-P450 inhibitor 1-aminobenzotriazole with 1 to rats significantly reduced the formation of M3 and prevented liver toxicity, whereas direct administration of M3 reproduced the toxicity. Structural changes were introduced to 1 to make the methoxypyridine ring less susceptible to P450 oxidation (compound 2), and addition of a methyl group to the benzylic carbon (compound 3) improved the pharmacokinetic profile. These changes culminated in the successful design of a clinical candidate 3 (AMG 511) that was devoid of liver toxicity in a 14-day rat toxicity study. Herein, we describe how a metabolism-based structure-activity relationship analysis allowed for the successful identification of a PI3K inhibitor devoid of off-target toxicity.
significant efforts to discover PI3K inhibitors have resulted in several compounds that are in various stages of clinical development (Engelman, 2009; Ihle and Powis, 2009; Kurtz and RayCoquard, 2012; Markman et al., 2010; Schettino et al., 2013; Vanhaesebroeck et al., 2010; Workman et al., 2010) .
Molecules 1-3, all from the pyridyltriazine series ( Fig. 1) , are potent and selective inhibitors of class Ia PI3K isoforms (Norman et al., 2012; Smith et al., 2012) . Administration of 1-3 to mice bearing solid tumor xenografts dependent on the PI3K pathway resulted in good pharmacodynamic responses (Norman et al., 2012; Smith et al., 2012) . Compound 1, the first molecule synthesized with acceptable drug-like properties, was tested in an exploratory 4-day rat toxicity study and resulted in hepatocellular and hepatobiliary toxicity. When 1 was dosed to bile-duct cannulated rats, less than 2% of the administered dose was observed in excreta and profiling of bile revealed the presence of oxidative metabolites. The structure of the metabolites was indicative of possible formation of electrophilic intermediate (s) and this led us to postulate that oxidative metabolite(s) of 1 may play a role in causing the hepatotoxicity.
In this paper, we describe the mechanistic drug disposition studies and toxicology experiments that were conducted with 1 to identify the cause of the liver toxicity. The findings from these experiments helped guide the structural design of other molecules (2 and 3) in the pyridyltriazine series, resolved the hepatotoxicity and ultimately led to the identification of a clinical candidate, compound 3 (AMG 511).
MATERIALS AND METHODS

Test Compounds
The structures of test compounds are shown in Figure 1 . Compounds 1, 4-(2-((6-methoxypyridin-3-yl)amino)-5-((4-(me thylsulfonyl)piperazin-1-yl)methyl)pyridin-3-yl)-6-methyl-1,3 ,5-triazin-2-amine; 2, 4-(2-((5-fluoro-6-methoxypyridin-3-yl) amino)-5-((4-(methylsulfonyl)piperazin-1-yl)methyl) pyridin-3 -yl)-6-methyl-1,3,5-triazin-2-amine; 3, (R)-4-(2-((5-fluoro-6-m ethoxypyridin -3-yl)amino)-5-(1-(4-(methylsulfonyl)piperazin -1-yl)ethyl)pyridin-3-yl)-6-methyl-1,3,5-triazin-2-amine; and M3, 5-((3-(4-amino-6-methyl-1,3,5-triazin-2-yl)-5-((4-(me thylsulfonyl)piperazin-1-yl)methyl) pyridin-2-yl)amino) pyridin-2(1H)-one were synthesized and characterized at Amgen (Norman et al., 2012; Smith et al., 2012) . [
14 C]-1 and [ 14 C]-3 with specific activities of 54.2 and 56.2 mCi/mmol, respectively, were synthesized incorporating a single 14 C-label at the methyl carbon on the triazine ring at Moravek Biochemicals (Brea, CA). 1-aminobenzotriazole (ABT) was purchased from Sigma-Aldrich (St. Louis, MO). All other reagents and materials were reagent grade or better and were used as supplied by vendors.
Test System
All in vivo studies except study 3 were conducted in female rats (Sprague Dawley; (9) (10) (11) (12) . Study 3 was conducted in male rats (Sprague Dawley; (9) (10) (11) (12) In Vivo Toxicology and Absorption, Distribution, Metabolism, and Excretion Studies
The general design and purpose of the in vivo rat studies are summarized in Table 1 . Female rats were used by default for toxicology screening studies due to their smaller size and associated lower drug requirements. Also by default, male rats were used in exploratory metabolism studies because of their larger size and an increased available blood volume. The exception to this paradigm was in study 8 (ADME study with compound 3) which was conducted in female rats to match the gender used in toxicology assessments.
Dose formulations
Dosing solutions were formulated by the Department of Pharmaceutics at Amgen. For intravenous (IV) dosing, test compounds were prepared in dimethyl sulfoxide (DMSO) to administer a 0.5-ml/kg dose volume. For oral (PO) dosing, vehicle control, ABT, and test compounds 1-3 were prepared to administer a 10-ml/kg dose volume at each target dose level. Each oral dosing formulation was prepared either as a solution or a suspension in 2% hydroxypropyl methylcellulose, 1% Pluronic F-68, 15% (hydroxypropyl)-␤-cyclodextrin in de-ionized water, with pH adjusted to 2.2 using methane sulfonic acid. For test compound M3, the formulation for the intraperitoneal (IP) route of administration remained the same as above except the pH was adjusted to 3. ABT was formulated in a saline solution (0.9% NaCl in water). For the radiolabeled absorption, distribution, metabolism, and excretion (ADME) studies, [ 14 C]-1 or [ 14 C]-3 was combined with the corresponding non-radiolabeled test compound in formulations as necessary to achieve the desired specific activity; doses were formulated as described above. Dose analyses were conducted pre and post the last dose administration and all dose preparations were determined to be within 90-110% of target concentrations.
Toxicology studies Dose levels for toxicology studies were based on exploratory pharmacokinetics and the measured potency of target inhibition determined in pharmacodynamics studies. The low dose levels were anticipated to be well tolerated, whereas high dose levels were anticipated to be the maximum tolerated doses. Histopathology, clinical pathology, and toxicokinetic (TK) evaluations were performed for each toxicology study. Necropsies were conducted 24 h after the last dose was administered. For clinical pathology urine was collected over night prior to necropsy and blood samples were collected from the descending aorta under isoflurane anesthesia at the time of necropsy. Euthanasia was conducted by exsanguination. Livers were collected, weighed, fixed in 10% neutral buffered formalin, embedded in paraffin, sectioned at 5-m thickness and stained with hematoxylin and eosin for light microscopy examination. Blood samples for clinical chemistry were collected into serum separator tubes. Blood samples for TK were collected into lithium heparin Vacutainer blood collection tubes on day 1 (at 24 h post first dose for 4-day studies; at 3, 7, 12, and 24 h post-dose for 10-or 14-day studies) and on the last day prior to necropsy (five time b PO doses were administered via oral gavage; IV dose was administered via an implanted jugular vein catheter. In ABT co-administered groups, ABT was orally administered 2 h prior to 1 (study 5) or M3 (study 6).
points: at pre-dose and post-dose, typically at 3, 7, 12, and 24 h). Blood samples were centrifuged at 4500 × g for 10 min and the serum (clinical chemistry) and the plasma (TK) were harvested for analysis. The serum clinical chemistry parameters, measured on an Olympus AU 440 clinical chemistry analyzer, were aspartate aminotransferase (AST), alanine aminotransferase (ALT), sorbitol dehydrogenase (SDH), glutamate dehydrogenase (GLDH), alkaline phosphatase (ALP), gamma glutamyltransferase (GGT), total bilirubin (TBIL), and total bile acids (TBAs). Statistical analysis was performed for groups with more than three animals using Pristima (Version 6.1.0 Build 54; Xybion Corp., Morris Plains, NJ). Analysis of variance (ANOVA) or non-parametric ANOVA (Kruskal-Wallis test) and multiple group comparison tests (Dunnett's for parametric or Dunn's test for nonparametric data) were used to analyze clinical chemistry and organ weight parameters at significance levels of 0.05 and 0.01. Dunn's test was also performed at a significance level of 0.001.
ADME studies
Rat ADME studies were conducted with compounds 1 and 3 to determine the mass balance and metabolite profiles in excreted matrices and circulating components in plasma. All rats in the mass balance studies underwent surgery to implant a catheter into their bile-duct with a duodenum return. Following a minimum 48-h acclimation period, and prior to drug administration, the catheter was cut and the end from the bile-duct was diverted for bile collection. The catheter into the duodenum was used to continuously infuse a solution of taurocholic acid (0.0134 g/ml) in saline (9-mg/ml NaCl, 0.5-mg/ml KCl) at a rate of 1 ml/h for the duration of the study.
All orally dosed animals were fasted overnight prior to dose administration. Food was returned 2 h post-dose administration. IV-dosed rats had an additional catheter implanted in their jugular vein to administer the dose and were not fasted prior to dose dosing. Following test compound administration, rats were singly housed in metabolism cages. Bile and urine were collected into pre-frozen (at −80
• C) BASi I-Cup devices (Bioanalytical Systems, Inc., West Lafayette, IN) at pre-determined post-dose time periods: 0-4, 4-8, and 8-24 h in study 3; 0-4, 4-8, 8-24, 24-48, and 48-72 h in studies 4 and 8. Feces were collected at room temperature post-dose at 0-24, 24-48, and 48-72 h in studies 4 and 8. After the final collection, each rat was sacrificed with carbon dioxide overexposure. Cages were subsequently rinsed to collect any residual radioactivity. All samples were stored at −80 • C immediately after collection until further analysis.
Analytical Methods
C analysis
Dose solutions, plasma, and excreta samples from the 14 C-ADME studies were analyzed for their total 14 C content. Duplicate aliquots of urine (100 l), bile (100 l), or 1:40 dilution of dosesolution (50 l) were added directly to scintillation cocktail (10 ml; UltimaGold, Perkin Elmer, Waltham, MA). Feces were homogenized in 70% ethanol in water using a high frequency mechanical homogenizer. Triplicate aliquots of homogenates were transferred to Combusto-Cones (Packard), weighed, air-dried, and combusted using sample oxidizer (Tri-carb 307; PerkinElmer). The resultant 14 CO2 was trapped with Carbo-Sorb (9 ml; PerkinElmer), followed by addition of a scintillation cocktail (9 ml; Permafluor, PerkinElmer). The radioactivity in all samples was quantified using a liquid scintillation analyzer (Tri-Carb LSC, Model 2900TR; PerkinElmer) with automatic quench correction using an external standard method. 14 C-administered dose and 14 C-dose recovery calculations were performed using Debra (version 5.7, Lablogic Inc., London, UK) software. Recoveries were expressed as percent of administered radioactive dose.
Liquid chromatography-mass spectrometry/mass spectrometry bioanalytical methods
Plasma samples from ADME and toxicity assessment studies were prepared for liquid chromatography-mass spectrometry (LC-MS) analysis by protein precipitation. For analysis of each test compound, calibration standards were prepared in plasma. Eleven calibration concentrations ranging from 0.5 to 5000 ng/ml were prepared by serial dilution of a 100-g/ml standard in DMSO spiked into control (non-dosed) rat plasma. A working solution of an internal standard (at 50 ng/ml) was prepared in acetonitrile (ACN) and added to plasma samples prior to protein precipitation. The bile and urine samples from the nonradiolabeled ADME study with 1 (study 3) were diluted 10-fold prior to LC-MS analysis and quantified using a plasma calibration curve.
Chromatographic separations were carried out on an ultrahigh-performance LC system (Prominence; Shimadzu Inc., Columbia, MD) with a reverse-phase column (Luna C18 (2) The lower and upper limits of quantification for each analyte were 0.5 and 5000 ng/ml, respectively. Bioanalytical data were acquired and processed using the Analyst program (Version 1.4.1; AB Sciex). The MS result tables were exported and the concentrations of each analyte were then calculated from a standard curve fitted by a weighted (1/x 2 ) linear regression in
Watson software (version 7.4; Thermo Fisher Scientific, San Jose, CA). Non-compartmental analysis was performed within Watson to determine the TK parameters.
HPLC-radiometric-Ion trap MS (LC-14 C-MS) methods
For urine and bile, 1% of the excreted volume from each time period was first pooled, vortex mixed, and centrifuged to remove particulates. For feces, 5% of the excreted amount at each time period was pooled. An aliquot was taken from the pooled feces, combined with approximately 20 volumes of extraction mixture (H 2 O/ACN/MeOH in 1:2:1 v/v/v), vortex mixed, and shaken vigorously for 3 h at 4
• C. The mixture was centrifuged at 5000 × g for 30 min and the supernatants were harvested. The extraction procedure was repeated two more times; the supernatants were then combined and dried in a vacuum centrifuge. The dried slurry was reconstituted in 500 l of 0.1% formic acid in H 2 O/ACN (80/20 v/v). The 14 C recovery from each preparation was greater than 90%. Chromatographic separations of 20-40-l aliquots of the extracts were performed on a reverse phase HPLC system in line with a photo-diode array (PDA) detector (Agilent 1290 system, Urine 32.9 ± 4.5 1.1 ± 1.7 0.9 ± 0.4 24.6 ± 8.3 Bile 29.8 ± 5.1 3.1 ± 1.8 0.6 ± 0.5 22.1 ± 4.0 Feces 35.4 ± 8.1 25.3 ± 7.6 0 9.8 ± 0.1 Total 98.1 ± 1.6 29.5 ± 6.0 1.5 ± 0.6 56.5 ± 11.9 The effluent from the PDA was split so that 0.2-ml/min flow was directed to the mass spectrometer and the remaining flow (0.5 ml/min) was directed to either an in-line flow radioactive detector (excreta sample extracts) or a fraction collector (plasma sample extracts). In-line 14 C detection was performed with a ␤- was counted on a microplate scintillation counter (TopCount NXT; PerkinElmer) using a normalized 14 C protocol. Radiochromatograms were reconstructed from the cpm/well raw data using the Laura software (version 4; IN/US systems). MS analyses were performed with an ion-trap mass spectrometer (LTQ; Thermo Fisher Scientific). Electrospray ionization was performed in the positive ion mode using nitrogen as sheath and auxiliary gas. MS tune parameters were optimized for 1. Full scan MS data were acquired for ions from m/z 210 to 1000 for all ions entering the ion-trap. Collision-induced-dependent (CID) MS2 and MS3 spectra were acquired via a data-dependent acquisition method on the three most intense ions from the preceding full scan and the most intense ion from preceding MS2 scan events, respectively. All data were acquired and processed using Xcalibur software (version 1.4; Thermo Fisher Scientific). Metabolites were identified using the MS and multistage CID data.
FIG. 3.
Summary of clinical chemistry and liver weight changes. (A) Selected clinical chemistry parameter values and (B) liver weight observations for individual rats in studies 1 (red triangles), 5 (green triangles), and 6 (blue triangles). The following parameters were statistically significant: Study 1. Statistics was not conducted due to low group size. Study 5. Compound 1 (20 mg/kg): ALP, GGT, TBIL, TBA at p Ͻ 0.05 and liver weight (% of total body weight) at p Ͻ 0.01. ABT (50 mg/kg): liver weights (absolute and% of total body weight) at p Ͻ 0.05; GLDH at p Ͻ 0.01. ABT and Compound 1: liver weight (% of total body weight) at p Ͻ 0.01. Study 6. Compound 1 (20 mg/kg): ALT, GLDH, ALP, GGT, TBIL, and TBA at p Ͻ 0.01; AST and SDH at p Ͻ 0.001; ABT and M3 (10 mg/kg): liver weights (absolute and% of total body weight) at p Ͻ 0.01.
RESULTS
Hepatotoxicity of Compounds 1 and 2 (Studies 1 and 2)
In exploratory toxicology studies, treatment with 1 and 2 resulted in increases in serum insulin levels and increases in serum and urine glucose levels that were reflective of the anticipated pharmacological response to inhibition of PI3K-associated signal transduction of the insulin receptor (Taniguchi et al., 2006) . In addition, hepatotoxicity was observed. The hepatic findings for studies 1 and 2 are summarized in Table 2 .
Compound 1 (study 1): Absolute and relative (percent of body weight) liver weights were elevated at the doses of 20 and 40 mg/kg/day compared with those dosed with the vehicle. Light microscopy evaluations are shown in Figure 2 . Histologic changes were centered on bile-ducts; observed changes were biliary epithelial hyperplasia and hypertrophy, periductular edema, biliary stasis, and acute peribiliary inflammatory infiltrates. Minimal hepatocellular single cell necrosis was observed in compound 1-treated groups. Serum markers of hepatocellular and hepatobiliary injury (AST, ALT, SDH, GLDH, ALP, GGT, TBA, and TBIL; shown in Fig. 3 ) were mildly to markedly increased in rats dosed with 20 or 40 mg/kg/day compared with those dosed with vehicle. A clear dose response was absent. As expected with increased serum TBIL, urine TBIL was increased at day 5 in rats dosed at 40 mg/kg/day. Additional clinical pathology changes included mildly to moderately increased triglycerides and cholesterol.
Compound 2 (study 2): There were no histological or clinical chemistry indicators of hepatic toxicity at 10 or 25 mg/kg/day. In animals dosed with 50 mg/kg/day of 2, changes were similar to those observed at 20 and 40-mg/kg treatment with 1, and included elevated absolute and relative (percent of body weight) liver weights, acute inflammation centered on bile-ducts, and hypertrophy of the biliary epithelium. Clinical chemistry values are shown in Supplementary figure 1. The changes were also similar to those observed with 1, and included mildly to moderately elevated serum AST, ALT, GLDH, TBIL, and GGT. Additional clinical pathology changes not observed with 1 included peripheral blood leukocyte and protein changes consistent with inflammation.
The TK of 1 and 2 are summarized in Table 3 .
ADME Results with Compound 1 (Studies 3 and 4)
Following administration of a single IV dose of 1 at 1 mg/kg (study 3), detectable concentrations of intact 1 were observed in urine and bile collected up to 8 h. The mean cumulative amount excreted intact in bile and urine was 5.30 and 0.83 g, respectively. Of the approximately 250-g dose administered to each rat; approximately 6.1 g (2.4%) was excreted intact. The exploratory ADME study revealed 1 was metabolized by the liver and the metabolites were excreted in bile. Mass balance and metabolite profiling were conducted following a single oral dose of [ 14 C]-1 (study 4). The cumulative excretion in 0-72 h following administration is summarized in Table 4 . The excellent overall recovery and the proportions of the 14 C-dose excreted in bile, urine, and feces indicate that 65-75% of the dose was absorbed into systemic circulation. Representative 14 C-chromatograms from pooled excreted matrices are shown in Figure 4 . The parent molecule (1) present in feces accounted for approximately 25% of the dose and was attributed to unabsorbed drug. M3 was the most significant metabolite present in feces and represented 10% of the dose. The most abundant component in bile and urine was metabolite M3 at 25% and 22% of the dose, respectively. Several other metabolites were also present in excreta but each was less than or equal to 2% of the dose, and based on their structures they could be rationalized as products derived from M3 following further metabolism. Structures of metabolites were proposed based on recordings of CID MS fragmentation patterns collected for each peak in the radiochromatogram, and by co-elution with available synthetic standards. The CID MS fragmentation pattern for 1 and its metabolite M3 are shown in Figure 5 . Analysis of MS fragmentation data for M3 indicated an oxidation at the methoxy carbon of the methoxypyridine ring in 1. The structure of M3 was confirmed with a synthetic standard. The structures of the other identified metabolites are shown in Figure 6 . The proposed biotransformation pathways of 1 in rat are shown in Figure 6 . The O-demethylation pathway accounted for approximately 58% of the administered oral dose.
Effect of ABT on Hepatotoxicity of Compound 1 (Study 5)
The hepatic findings from study 5 are summarized in Table 2 and shown in Figures 3 and 7 . Animals dosed with ABT alone had increased numbers of mitotic figures in hepatocytes and increased liver weights, as previously reported (Meschter et al., 1994) . No test compound-related hepatotoxicity changes were observed in rats administered with vehicle control (Fig. 7A) or 5 mg/kg of 1 with or without ABT (data not shown). As anticipated, females administered with 1 at 20 mg/kg/day had clinical and anatomic pathology changes indicative of hepatotoxicity (Fig. 7B) . Microscopic changes in animals treated with 20 mg/kg/day of 1 were consistent with findings observed in study 1. These effects were partially or completely attenuated by the addition of ABT at 50 mg/kg/day (Fig. 7C) .
The TK of 1 and its metabolite M3 were determined and are summarized in Table 3 . High circulating levels of 1 and M3 were observed in groups administered with 1 alone. Administration of ABT prior to 1 affected the plasma concentrations of both 1 and M3. The C max and AUC were significantly higher for 1 and significantly lower for M3 in the group treated with both 1 and ABT compared with the group dosed only with 1.
Effect of M3 on Hepatotoxicity (Study 6)
The M3-related hepatic findings are summarized in Table 2 and shown in Figures 3 and 7 . Treatment with M3 at 10 mg/kg caused minimal increases in GLDH (mean of 53.4 U/l compared with 30.1 U/l in controls) and TBA (Fig. 3) ; minimal to mild bile-duct hypertrophy/hyperplasia; low incidence of minimal apoptosis/single cell necrosis of bile-duct; and chronic active periportal inflammation (Fig. 7D) . These changes were similar in animals co-administered or not co-administered with ABT at 50 mg/kg. Animals administered 20 mg/kg of 1 had the same findings as described for study 1. The TK data from study 6 are summarized in Table 3 . Significant circulating levels of M3 were observed in rats dosed with either M3 via the IP route or 1 administered PO; although the M3 exposure in rats dosed with M3 alone was approximately 38% of AUC obtained upon dosing 1. Co-dosing M3 with ABT did not significantly alter the TK of M3; the maximal concentration and AUC of M3 both decreased approximately 15% relative to the corresponding levels in the non-ABT group.
Effects of Compound 3 on Hepatotoxicity (Study 7)
There was no clinical pathology (shown in Supplementary fig.  1 ) or histological changes indicative of liver toxicity in animals administered up to 10 mg/kg/day of 3. Hepatotoxicity was not observed with 3 despite reaching exposure (AUC) levels that resulted in elevations in serum insulin resulting from on-target activity, and that were similar to the compound 1 exposures associated with hepatic toxicity (Table 6 ).
ADME Results with Compound 3 (Study 8)
The mass balance and excretion profiles of [ 14 C]-3 following a single IV dose are summarized in Table 5 . Approximately 86% of the administered dose of [ 14 C]-3 was recovered in 72 h. Oxidative metabolism accounted for the majority of the clearance pathway (∼75%) with oxidations observed on the methoxypyridine, methyl-benzyl-methylsulfone, and the triazine ring moieties. Three metabolites arising from the demethylation of the methoxypyridine moiety (i.e., O-demethylation pathway) were observed ( Table 5 ). The sum of all metabolites from the Odemethylation pathway accounted for a maximum of 28% of the administered dose.
DISCUSSION
A summary of the findings from the mechanistic PK, ADME, and toxicology studies is shown in Figure 8 . The TK and pharmacology comparisons across studies with the different test compounds are summarized in Table 6 .
Hepatotoxicity Findings
Compound 1 was the first of a series of pyridyltriazine molecules exhibiting a robust pharmacokinetic-pharmacodynamic relationship demonstrated by inhibition of the PI3K/Akt pathway in vivo in a mouse model. In addition, it potently inhibited tumor growth in a U87 MG glioblastoma xenograft model with an activated PI3K/Akt pathway (Smith et al., 2012) . Compound 1 was therefore advanced for an evaluation in a 4-day exploratory rat toxicity study (study 1). Following repeated dose administration of 1, liver changes were observed in both the clinical chemistry and histopathology readouts. Histologic changes on day 5 centered on the bile-ducts, and clinical pathology changes indicated hepatocellular and hepatobiliary injury. The liver effects were hypothesized to be unrelated to target inhibition because molecules from other chemotypes (D'Angelo et al., 2011; Nishimura et al., 2011; Stec et al., 2011) were devoid of such hepatotoxicity, but were at least equipotent in their ability to inhibit the PI3K isoforms in vitro and exhibited the anticipated pharmacological effects in rats.
Mechanistic investigations to determine the importance of M3 formation in toxicity
The exploratory ADME study (study 3) revealed that 1 underwent extensive metabolism with only 2.4% of the administered IV dose of 1 recovered intact in excreta. Qualitative LC-MS metabolite profiling of bile and urine revealed the presence of oxidative metabolites (mainly metabolite M3). M3 was also formed in in vitro incubations of 1 in rat liver microsomes fortified with NADPH. M3 formation was abrogated in the presence of ketoconazole (data not shown). The combined in vitro and in vivo ADME data indicated metabolism was the major clearance pathway for 1 in rat. The ADME data led to a hypothesis that P450-mediated hepatic metabolite(s) rather than the parent molecule could either cause or at least be a significant contributor to the observed hepatotoxicity arising from 1. A set of in vivo ADME mechanistic and toxicology (including TK) experiments was then undertaken to distinguish the contributions of the intact drug and the oxidative metabolite(s) toward the observed toxicity. The ADME study (study 4) with [ 14 C]-1 confirmed oxidative metabolism was the predominant in vivo clearance pathway for 1 in rat. Metabolic profiling of excreta revealed the importance of O-demethylation, leading to the formation of M3 and other related metabolites, in the clearance of 1. In aggregate 63-76% of the absorbed dose underwent O-demethylation. [ 14 C]-1 ADME studies identified M3 as a candidate for the proximal toxic entity. ABT is an effective non-specific in vivo inhibitor of cytochromes P450 (Mico et al., 1988) . QD administration of 50 mg/kg ABT has been demonstrated to provide adequate plasma concentrations to sustain P450 inhibition over 24 h (Balani et al., 2002) . This sustained inhibition was confirmed with in-house studies at Amgen (data not shown). An exploratory singledose PK experiment was performed to guide the selection of dose levels of 1 in study 5. Compound 1 was dosed at 20 mg/kg as a single-agent or following administration of ABT. Coadministration with ABT and 1 resulted in a 4-fold increase in the plasma AUC exposure of 1. Accordingly, a 5-mg/kg dose level of 1 co-administered with ABT was selected to achieve approximately the same AUC as 1 dosed alone at 20 mg/kg (data not shown).
A 4-day rat toxicology experiment (study 5) was then conducted dosing 1 at two dose levels (5 and 20 mg/kg) with and without ABT administration. The clinical chemistry and anatomic pathology indications of hepatobiliary or hepatocellular injury observed in study 1 were recapitulated in study 5 in animals dosed with 1 at 20 mg/kg/day. Evidence of hepatotoxicity was almost completely eliminated in the animals dosed with both ABT and 1. The plasma AUC level of 1 at 20-mg/kg dose level (study 5; Table 3 ) was 2.4-fold higher with ABT administration; thus, significantly increased in the presence of ABT. In contrast, M3 AUC in study 5 was 97% lower in ABT-dosed group; thus, M3 formation was substantially diminished in the presence of ABT. Therefore, ABT suppressed the P450-mediated metabolism of 1 and attenuated hepatotoxicity. This study reinforced the hypothesis that M3 may indeed be the causative agent of the observed hepatotoxic effects from 1 and led to study 6. The pharmacokinetics of M3 was determined prior to study 6; M3 clearance was greater than liver blood flow clearance (4.8 l/h/kg) and bioavailability following oral dosing was 0% due to its poor solubility. Bioavailability improved to 100% upon administration by the IP route. Study 6 included groups dosed with 1 (as a comparator group to recapitulate the previously observed hepatic findings), M3, and an additional M3 + ABT arm. The ABT arm was included to investigate whether a metabolite (a putative quinone-imine) arising from a P450-mediated oxidation of M3 could possibly be the culprit. The clinical chemistry and histopathology findings of hepatic injury were recapitulated in all three groups even though the exposure of M3 was approximately 2-fold less than what was observed upon dosing 1 in study 5. Co-dosing with ABT did not alleviate the hepatotoxicity. Study 6 confirmed M3 was the causative agent of the hepatotoxicity that was observed upon dosing 1.
M3 had micromolar activity against human PI3K isoforms in biochemical assays (Norman et al., 2012) . Bioactivation of 5-amino-pyridin-2-ol tautomer in M3 could result in a quinoneimine reactive intermediate, however, no GSH conjugates were detected following incubations with either 1 or M3 with rat hepatocytes or liver microsomes supplemented with NADPH and GSH. In addition, M3 was not an inducer of rat hepatic P450 enzymes and did not affect the function of the common hepatic transporters (P-glycoprotein, organic anion polypeptide transporter/multidrug resistant protein, breast cancer resistant protein, and bile-salt export pump). No clear mechanism of M3 hepatobiliary toxicity was identified.
Structure-Activity Relationship for Hepatotoxicity
Introduction of an electronegative fluorine group at the 3-position in the pyridine ring of 1 reduced its electron density and thus decreased the susceptibility of the methoxy-carbon to P450 oxidation. This synthetic strategy produced 2, wherein a metabolite profile following incubation in rat hepatocytes revealed the O-demethylation was significantly reduced (Norman et al., 2012) . Also, longer dosing (10 days of 2 vs. 4 days of 1) with higher doses (50 mg/kg of 2 vs. 20 mg/kg of 1) was required to cause hepatotoxicity (Table 6) .
Compound 3 built upon favorable pharmacology and toxicity profile over compound 2. A methyl group was added to the benzylic carbon bridging the aminopyridine and piperazine rings and this change blocked metabolism around the piperazine moiety and improved its PK properties (Norman et al., 2012) . P450-mediated metabolism remained the predominant clearance pathway for 3; however, the O-demethylation metabolism pathway accounted for only 28% of administered dose; a reduction of 40-46% compared with 1. Introduction of the methyl group in 3 also increased its potency against PI3K class I isoforms and lower doses were required to elicit the pharmacological response (Norman et al., 2012) . No clinical chemistry or microscopic changes indicative of hepatotoxicity were observed after 14 days of daily treatment with 3 at 10 mg/kg/day (Table  6 ). The plasma exposure for 3 at its maximum dose was greater than the exposure of 1 at the minimum dose (20 mg/kg/day; Table 6) associated with hepatotoxicity.
Compound 3 is a potent inhibitor of the class Ia PI3K isoforms and has excellent selectivity over mTOR, related phosphatidylinositol kinases, and a broad panel of protein kinases (Norman et al., 2012) . Compound 3 inhibited pAKT in tumor tissue in a dose-and time-dependent manner (Norman et al., 2012) and in-hibited tumor growth in PTEN-null, KRAS mutant, and HER2-amplified xenograft models. At 10 mg/kg, 3 resulted in higher serum insulin compared with 1 at 20 mg/kg or 2 at 50 mg/kg (Table 6) . Compound 3 was nominated as a clinical candidate, AMG 511 (Norman et al., 2012) .
CONCLUSION
Administration of the lead molecules 1 and 2 from a triazine series caused increases in values for clinical chemistry hepatotoxicity markers and microscopic hepatobiliary lesions in rat. Tiered mechanistic PK and ADME experiments were undertaken with 1 to determine the causative agent. ADME studies with 1 pinpointed a P450-mediated O-demethylated pyridine metabolite M3 as a dominant component and potential candidate for the proximal toxic entity causing the hepatotoxicity. Co-administration of 1 with ABT suppressed the P450-mediated metabolism of compound 1 to M3 and abolished the observed toxicity. Dosing with M3 alone reproduced the clinical chemistry and histopathology changes that were observed with 1 confirming that it was the proximal entity causing the hepatotoxicity. This work used metabolism-based structure-activity relationship analysis to successfully identify 3 (AMG 511) as a clinical candidate devoid of the off-target metabolite-driven liver toxicity.
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